Bob Woodruff Foundation Receives Donation from Ferring Pharmaceuticals
Launched in 2017, the Foundation's VIVA program provides grants and personalized support to veterans with service-connected fertility challenges who want to grow their families and who may not qualify for Veterans Affairs funding. In addition to in vitro fertilization (IVF) grants to veterans, BWF helps veterans learn about IVF and other fertility services provided by the VA. To date, BWF has provided more than 270 VIVA grants and welcomed 77 babies.
"The Foundation is grateful to Ferring Pharmaceuticals for its generous support of our VIVA, program," said
"We applaud the work of the Bob Woodruff Foundation, and we're honored to help support veterans through the VIVA program. We understand that the path to parenthood can be challenging for many," said
Ferring also provides support to eligible veterans and their spouses seeking IVF treatment through its Heart for Heroes program. For more information, please visit the Ferring Fertility website.
About the Bob Woodruff Foundation
The Bob Woodruff Foundation was founded in 2006 after reporter
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In
Media Contact:
646.831.1067
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/bob-woodruff-foundation-receives-donation-from-ferring-pharmaceuticals-302164288.html
SOURCE Bob Woodruff Foundation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MagIron Demonstrates Excellent Direct Reduction Pellet Quality in Latest Test Program
- Essity acquires feminine care business in Brazil
- XRP’s $50 Debate and HYPE’s SEC Push Set the Stage for Apeing, the Upcoming Crypto Coin Making Waves Ahead of Its Presale
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share